Boston Scientific Corporation $BSX Stock Purchased by Mawer Investment Management Ltd.

Mawer Investment Management Ltd. raised its stake in Boston Scientific Corporation (NYSE:BSX) by 70.5% in the third quarter, Holdings Channel reports. The firm owned 904,543 shares of the medical equipment provider’s stock after acquiring an additional 374,010 shares during the quarter. Mawer Investment Management Ltd.’s holdings in Boston Scientific were worth $39,483,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of BSX. Diversified Trust Co increased its position in shares of Boston Scientific by 204.8% during the 3rd quarter. Diversified Trust Co now owns 33,326 shares of the medical equipment provider’s stock worth $1,455,000 after purchasing an additional 22,391 shares during the last quarter. Aberdeen Group plc boosted its holdings in shares of Boston Scientific by 3.5% in the 3rd quarter. Aberdeen Group plc now owns 3,175,308 shares of the medical equipment provider’s stock valued at $138,602,000 after buying an additional 108,682 shares during the last quarter. Moors & Cabot Inc. boosted its holdings in shares of Boston Scientific by 235.7% in the 3rd quarter. Moors & Cabot Inc. now owns 100,750 shares of the medical equipment provider’s stock valued at $4,398,000 after buying an additional 70,740 shares during the last quarter. Compass Capital Management Inc. grew its stake in shares of Boston Scientific by 16.9% in the third quarter. Compass Capital Management Inc. now owns 1,004,548 shares of the medical equipment provider’s stock valued at $43,849,000 after buying an additional 145,018 shares in the last quarter. Finally, SVB Wealth LLC grew its stake in shares of Boston Scientific by 457.7% in the third quarter. SVB Wealth LLC now owns 31,868 shares of the medical equipment provider’s stock valued at $1,391,000 after buying an additional 26,154 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on BSX shares. Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. JPMorgan Chase & Co. cut shares of Boston Scientific from an “overweight” rating to a “neutral” rating and set a $46.00 price target for the company. in a research note on Wednesday, October 28th. Piper Sandler decreased their price objective on shares of Boston Scientific from $65.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday, July 29th. Needham & Company LLC lowered their price objective on shares of Boston Scientific from $57.00 to $48.00 and set a “buy” rating on the stock in a research note on Wednesday, October 28th. Finally, Canaccord Genuity Group lowered their price objective on shares of Boston Scientific from $66.00 to $48.00 and set a “buy” rating on the stock in a research note on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and a consensus price target of $61.43.

Boston Scientific Stock Performance

Shares of NYSE:BSX traded up $0.13 on Friday, hitting $44.33. The company had a trading volume of 9,698,273 shares, compared to its average volume of 20,222,538. The stock has a market cap of $64.25 billion, a price-to-earnings ratio of 18.78, a P/E/G ratio of 1.31 and a beta of 0.60. The stock has a 50 day moving average price of $44.00 and a 200 day moving average price of $54.50. Boston Scientific Corporation has a 1-year low of $39.57 and a 1-year high of $104.61. The company has a current ratio of 1.36, a quick ratio of 0.81 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.73. The company had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. Boston Scientific’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.75 EPS. Analysts expect that Boston Scientific Corporation will post 3.17 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.